Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion. The main object of the takeover is ...

Merck now finds itself in the same precarious ... and acquisitions like the $11 billion purchase of immunology-focused ...

Merck has taken steps in mergers and acquisition to diversify its pipeline and product offerings, including the $10.8 billion acquisition of Prometheus Biosciences and a major licensing deal with ...

Merck issued a US$6bn jumbo bond on Monday to help fund its US$10.8bn acquisition of Prometheus Biosciences that will give the pharmaceutical giant a foothold in therapies for immune diseases as it ...

(1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue ...